Julia Piasecki

1.2k total citations
22 papers, 403 citations indexed

About

Julia Piasecki is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Julia Piasecki has authored 22 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Julia Piasecki's work include CAR-T cell therapy research (15 papers), Multiple Myeloma Research and Treatments (7 papers) and Biosimilars and Bioanalytical Methods (6 papers). Julia Piasecki is often cited by papers focused on CAR-T cell therapy research (15 papers), Multiple Myeloma Research and Treatments (7 papers) and Biosimilars and Bioanalytical Methods (6 papers). Julia Piasecki collaborates with scholars based in United States, Germany and Switzerland. Julia Piasecki's co-authors include Pamela M. Holland, Todd DeVries, Sham Mailankody, John Byon, Andrzej Jakubowiak, Safiyyah Ziyad, Michelle Blake, William Bensinger, Myo Htut and Kelvin P. Lee and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Cell.

In The Last Decade

Julia Piasecki

21 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julia Piasecki United States	7	260	232	142	87	64	22	403
Kathryn Ruisaard United States	9	324 1.2×	160 0.7×	272 1.9×	129 1.5×	77 1.2×	16	507
Dirk Hönemann Australia	9	314 1.2×	202 0.9×	227 1.6×	112 1.3×	121 1.9×	13	511
Stephanie Silveria United States	5	328 1.3×	223 1.0×	472 3.3×	84 1.0×	32 0.5×	6	723
Daijing Yuan China	7	314 1.2×	114 0.5×	149 1.0×	39 0.4×	36 0.6×	10	402
Kevin M. Friedman United States	8	405 1.6×	193 0.8×	283 2.0×	55 0.6×	67 1.0×	15	530
Andrea V. Lopez United States	8	503 1.9×	204 0.9×	229 1.6×	123 1.4×	63 1.0×	10	586
Tamara Laskowski United States	7	395 1.5×	201 0.9×	403 2.8×	76 0.9×	46 0.7×	8	645
Ryan Bjordahl United States	13	510 2.0×	197 0.8×	559 3.9×	66 0.8×	66 1.0×	51	747
Diana Campillo-Davó Belgium	14	377 1.4×	248 1.1×	309 2.2×	89 1.0×	90 1.4×	25	617

Countries citing papers authored by Julia Piasecki

Since Specialization

Citations

This map shows the geographic impact of Julia Piasecki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Piasecki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Piasecki more than expected).

Fields of papers citing papers by Julia Piasecki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Piasecki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Piasecki. The network helps show where Julia Piasecki may publish in the future.

Co-authorship network of co-authors of Julia Piasecki

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Piasecki. A scholar is included among the top collaborators of Julia Piasecki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Piasecki. Julia Piasecki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Hongxiang, Yan Li, Julia Piasecki, et al.. (2025). Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 31(6). 1163–1171. 3 indexed citations

Wu, Fan, Jian Zhou, Madhan Masilamani, et al.. (2025). Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class–Exposed Relapsed/Refractory Multiple Myeloma. Clinical Pharmacokinetics. 64(7). 1119–1132. 2 indexed citations

Wu, Fan, Joseph W. Burnett, Madhan Masilamani, et al.. (2025). Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple‐Class‐Exposed Relapsed/Refractory Multiple Myeloma. The Journal of Clinical Pharmacology. 65(11). 1568–1576.

Hu, Hongxiang, et al.. (2024). Population Cellular Kinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Multiple Myeloma. 1 indexed citations

Thompson, Ethan, Julia Piasecki, Paula Rodríguez‐Otero, et al.. (2024). Association of patient (pt) factors and pharmacodynamic biomarkers with progression-free survival (PFS) after idecabtagene vicleucel (ide-cel) in pts from KarMMa-3.. Journal of Clinical Oncology. 42(16_suppl). 7527–7527. 2 indexed citations

Piasecki, Julia, Keyur Desai, Ethan Thompson, et al.. (2023). P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA. HemaSphere. 7(S3). e7421475–e7421475. 1 indexed citations

Piasecki, Julia, Keyur Desai, Ethan Thompson, et al.. (2023). Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 41(16_suppl). 8031–8031. 2 indexed citations

Stong, Nicholas, Ethan Thompson, Amy Xu, et al.. (2023). Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel).. Journal of Clinical Oncology. 41(16_suppl). 8035–8035. 1 indexed citations

Costa, Luciano J., Sham Mailankody, Paul Shaughnessy, et al.. (2021). Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).. Journal of Clinical Oncology. 39(15_suppl). 2537–2537. 9 indexed citations

10.

Colonna, Lucrezia, Garnet Navarro, Todd DeVries, et al.. (2020). Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence. Blood. 136(Supplement 1). 11–12. 15 indexed citations

11.

Piasecki, Julia, Todd DeVries, Aditya Radhakrishnan, et al.. (2020). Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011). Blood. 136(Supplement 1). 2–3. 6 indexed citations

12.

Mailankody, Sham, Myo Htut, Kelvin P. Lee, et al.. (2018). JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE). Blood. 132(Supplement 1). 957–957. 88 indexed citations

13.

Moesta, Achim K., Keegan S. Cooke, Julia Piasecki, et al.. (2017). Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade. Clinical Cancer Research. 23(20). 6190–6202. 81 indexed citations

14.

Vries, P.C. de, et al.. (2017). Tucatinib, a HER2 selective kinase inhibitor, is active in patient derived xenograft (PDX) models of HER2-amplified colorectal, esophageal and gastric cancers. Annals of Oncology. 28. v576–v576. 5 indexed citations

15.

Piasecki, Julia, Kenneth Brasel, Robert Rosler, Kevin Klucher, & Scott Peterson. (2017). Abstract 578: Discovery and characterization of novel antagonistic antibodies that bind with high affinity to human, cynomolgus, and murine TIGIT, an immune checkpoint receptor. Cancer Research. 77(13_Supplement). 578–578. 2 indexed citations

16.

Piasecki, Julia, Tiep Le, Rafael Ponce, & Courtney Beers. (2015). Abstract 258: Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade. Cancer Research. 75(15_Supplement). 258–258. 3 indexed citations

17.

Piasecki, Julia, et al.. (2015). Abstract 4287: Talimogene laherparepvec activates systemic T-cell-mediated anti-tumor immunity. Cancer Research. 75(15_Supplement). 4287–4287. 4 indexed citations

18.

Graves, Jonathan D., Jennifer J. Kordich, Tzu-Hsuan Huang, et al.. (2014). Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity. Cancer Cell. 26(2). 177–189. 137 indexed citations

19.

Holland, Pamela M., Robert E. Miller, Jon C. Jones, et al.. (2010). Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biology & Therapy. 9(7). 539–550. 33 indexed citations

20.

Piasecki, Julia, et al.. (2007). Induction of Transgene-Specific Cytotoxic T Lymphocyte Responses After Transplantation of Gene-Modified CD34 ⁺ Cells Despite Nonablative Immunosuppressive Conditioning. Human Gene Therapy. 19(1). 103–107. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact